Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer A Phase 3 Randomized Clinical Trial

This study (n=433; median age 78 years) found carboplatin plus pemetrexed followed by pemetrexed maintenance was non-inferior to docetaxel monotherapy with regard to overall survival (HR 0.850; 95% CI 0.684-1.056; P for non-inferiority = 0.003), with differing toxicity.


JAMA Oncology